Table 1

Baseline patient characteristics
Characteristic Placebo (n = 45) Alfentanilb (n = 45) P value
Male (%) 44.4 (20/45) 31.1 (14/45) 0.28
Age (years) 62.2 62.7 0.86
Weight (kg) 75.5 76.3 0.83
Height (cm) 172 170 0.41
BMI (kg/m2) 25.6 26.2 0.59
Education (%) 0.83
primary 6.7 (3/45) 6.7 (3/45)
secondary 53.3 (24/45) 46.7 (21/45)
tertiary 40.0 (18/45) 46.7 (21/45)
Ethnicity (%) 0.90
Dutch 93.3 (42/45) 91.1 (41/45)
Surinam 4.4 (2/45) 6.7 (3/45)
other 2.2 (1/45) 2.2 (1/45)
First CT colonography (%) 100 (45/45) 100 (45/45) 1.00
Indication abdominal pain (%) 29.5 (13/44) 15.9 (7/44) 0.20
Spasmolytic (%): 0.60
buscopan 86.7 (39/45) 84.4 (38/45)
glucagon 13.3 (6/45) 13.3 (6/45)
no 0 (0/45) 2.2 (1/45)
Oxygen saturation (%SpO2) 98 98 0.47
Heart rate (b/m) 77.8 79.0 0.70
Systolic blood pressure (mmHg) 155 158 0.59
Diastolic blood pressure (mmHg) 86 89 0.28
Expected burden (1–5) 3 3 0.31
Expected pain (1–5) 3 3 0.46

This table shows mean values, unless indicated otherwise; medians are presented for oxygen saturation, expected pain and burden.

For all percentage the numbers are given between brackets. No significant differences were present between baseline characteristics of the two groups.

Boellaard et al.

Boellaard et al. BMC Gastroenterology 2013 13:94   doi:10.1186/1471-230X-13-94

Open Data